net income attributable to equity holders of sanofi

  non-controlling interests

  share of undistributed earnings from investments accounted for using the equity method

  depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets

  gains and losses on disposals of non-current assets, net of tax

  net change in deferred taxes

  net change in non-current provisions and other non-current liabilities

  cost of employee benefits

  impact of the workdown of acquired inventories remeasured at fair value

  other profit or loss items with no cash effect on cash flows generated by operating activities

  operating cash flow before changes in working capital

  (increase)/decrease in inventories

  (increase)/decrease in accounts receivable

  increase/(decrease) in accounts payable

  net change in other current assets and other current liabilities

  net cash provided by/

  acquisitions of property, plant and equipment and intangible assets

  acquisitions of consolidated undertakings and investments accounted for using the equity method

  acquisitions of other equity investments

  proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax

  disposal of consolidated undertakings and investments accounted for using the equity method, net of tax

  net change in other non-current assets

  net cash provided by/(used in) investing activities

  issuance of sanofi shares

  dividends paid:

  •to shareholders of sanofi

  •to non-controlling interests

  payments received/(made) on changes of ownership interest in a subsidiary without loss of control

  additional long-term debt contracted

  repayments of long-term debt

  repayments of lease liabilities

  net change in short-term debt and other financial instruments

  acquisitions of treasury shares

  net cash provided by/(used in) financing activities

  impact of exchange rates on cash and cash equivalents

  net change in cash and cash equivalents

  cash and cash equivalents, beginning of period

  cash and cash equivalents, end of period

  f-8

  gain on regeneron investment arising from transaction of may 29, 2020, net of tax

  net proceeds from sale of regeneron shares on may 29, 2020

  net (income)/loss of the exchanged/held-for-exchange animal health business

  operating cash flow before changes in working capital and excluding the exchanged/held-for-exchange animal health business

  net cash provided by/(used in) investing activities excluding the exchanged/held-for-exchange animal health business

  net cash inflow from the exchange of the animal health business for bi’s consumer healthcare business

  net cash provided by/(used in) financing activities excluding the exchanged/held-for-exchange animal health business

  sanofi form 20-f 2021

  non-controlling interests, excluding bms

  other profit or loss items with no cash effect

  •to non-controlling interests, excluding bms

  net change in short-term debt

  sanofi form 20-f 2020 |

  share of undistributed earnings of associates and joint ventures

  depreciation, amortization and impairment of property, plant and equipment and intangible assets

  net change in provisions

  unrealized (gains)/losses recognized in income

  net change in other current assets, current financial assets and other current liabilities

  net cash provided by/(used in) operating activities

  acquisitions of investments in consolidated undertakings, net of cash acquired

  acquisitions of available-for-sale financial assets

  net change in loans and other financial assets

  • to shareholders of sanofi

  • to non-controlling interests, excluding bms

  transactions with non-controlling interests, other than dividends

  acquisition of treasury shares

  disposals of treasury shares, net of tax

  impact of merial cash and cash equivalents

  further to the announcement that merial and intervet/schering-plough are to be maintained as separate businesses operating independently, the line items in the statement of cash flows for the comparative periods (2010 and 2009) include cash flows generated by the operating investing and financing activities of merial. the cash and cash equivalents of merial were reported in the balance sheet in assets held for sale or exchange as of december 31, 2009 and 2010.

  – net change in cash and cash equivalents excluding merial

  – net change in cash and cash equivalents of merial

  – net change in cash and cash equivalents including merial

  see note c.1. including available-for-sale financial assets. including:

  – income tax paid

  – interest paid

  – interest received

  – dividends received from non-consolidated entities

  property, plant and equipment, intangible assets, investments in consolidated entities and other non-current financial assets.

  net income attributable to equity holders of sanofi-aventis

  net income from the held-for-exchange merial business

  dividends received from merial

  net change in loans and other non-current financial assets

  issuance of sanofi-aventis shares

  • to shareholders of sanofi-aventis

  income tax paid

  interest paid

  interest received

  dividends received from non-consolidated entities

  property, plant and equipment, intangible assets, investments in consolidated undertakings and other non-current financial assets.

  net income attributable to equity holders of the company

  minority interests, excluding bms

  share of undistributed earnings of associates

  net change in other current assets, financial assets (current) and other current liabilities

  • to sanofi-aventis shareholders

  • to minority shareholders, excluding bms

  additional long-term borrowings

  repayments of long-term borrowings

  net change in short-term borrowings

  see note c.1.

  impact of workdown of aventis inventories remeasured at fair value, net of tax

  unrealized gains and losses recognized in income

  increase/(decrease) in accounts payable and accrued expenses

  net change in other current assets, financial assets — current and other current liabilities

  net cash from operating activities

  net cash from investing activities

  net change in other current assets, financial assets – current and other current liabilities

  net income

  minority interests other than bms

  share of earnings of associates, net of dividend and equivalents received

  depreciation and amortization

  gains and losses on disposals of non-current assets

  unrealized gains and losses recognized in income statement

  net change in other current assets, financial assets (current) & other current liabilities

  acquisitions of property, plant & equipment and intangibles

  acquisition of aventis, net of cash acquired

  proceeds from disposals of property, plant and equipment, intangibles and other non-current assets

  • to minority shareholders other than bms

  acquisitions and disposals of treasury shares

  minority interests

  share in undistributed earnings of equity investees

  gains on disposals of fixed assets, net of income taxes

  provisions, long-term deferred taxes and other

  expensing of research and development and impact of remeasurement of inventories, net of income taxes

  dividends received from equity investees

  change in other operating assets and liabilities

  other acquisitions of investments

  proceeds from disposals of fixed assets, net of income taxes

  net change in loans, long-term advances and other investing cash flows

  capital contribution from minority shareholders

  - to sanofi-aventis shareholders

  - to minority shareholders of subsidiaries

  acquisitions of treasury shares net of disposals, including disposals made in connection with stock options

  net cash from financing activities

  acquisitions of investments

  issuance of sanofi-synthélabo shares

  – to sanofi-synthélabo shareholders

  – to minority shareholders of subsidiaries

  acquisitions of treasury shares net of disposals, including disposals made in connection with stock option plans

  changes in working capital

  total investments

  asset disposals and other items

  change in borrowings and other items

  dividends paid

  repurchase of own shares

  – dividends received from equity investees

  – (increase)/decrease in inventories

  – (increase)/decrease in accounts receivable

  – increase/(decrease) in accounts payable

  – change in other operating assets and liabilities